[breadcrumb]
Anti-angiogenesis drugs, sometimes called angiogenesis inhibitors, target vascular endothelial growth factor (VEGF) molecules.[1] Normally, these molecules send signals to nearby tissues to prompt the growth of additional blood vessels. Since tumors need a blood supply to survive, blocking these pathways in theory cuts off the tumor’s supply to growth factors.
An opposing theory is that the drugs actually promote growth of normalized blood vessel tissues within tumors, improving the delivery of chemotherapy and other drugs.[2]
Currently, Avastin (bevacizumab) is one of the most commonly prescribed drugs of this type.
Avastin (bevacizumab)
Avastin (generic name bevacizumab) is a drug developed from Chinese hamster cells and used as an anti-angiogenesis drug in certain clinical trials. It is administered intravenously, often in conjunction with chemotherapy drugs.[3]
The drug was originally approved for use in treating certain forms of age-related macular degeneration (AMD).[4]
Early trials in mesothelioma patients suggest that Avastin in combination with pemetrexed and cisplatin could provide palliative benefits in terms of quality of life, especially through the management of pain and diminishing of peripheral neuropathy.[5] Further study is needed to evaluate the drug’s effectiveness as a mesothelioma treatment.
[1] https://www.mdanderson.org/treatment-options/angiogenesis-inhibitors.html
[2] https://hms.harvard.edu/news/why-antiangiogenesis-fails
[3] https://www.rxlist.com/avastin-drug.htm#side_effects
[4] https://www.aao.org/eye-health/drugs/avastin
[5] https://clincancerres.aacrjournals.org/content/early/2019/06/07/1078-0432.CCR-18-2860
